Plenary Session

Co-Chair(s)

• 

  Evangelos Terpos, MD (he/him/his)

  Professor
  Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
  Athens, Attiki, Greece
• 

  Sundar Jagannath, MD, FASCO (he/him/his)

  Chair for Multiple Myeloma and Professor of Medicine
  Mount Sinai Medical Center, New York, NY, USA
  New York, New York

Presentations:

• 13:15 - 13:19 East Coast USA Time

  Abstract Introduction
  

  Speaker: Adam D. Cohen, MD – Perelman School of Medicine, University of Pennsylvania
• 13:19 - 13:37 East Coast USA Time

  (OA-16) BCMA CAR T-Cell Therapy in Newly Diagnosed Primary Plasma Cell Leukemia Ineligible for Transplantation: An Open Label, Single-arm, Phase 2 Study (CAREMM-002)
  

  Abstract Presenter: Chenxing Du, MD, PhD (she/her/hers) – Institute of Hematology and Blood Diseases Hospital
• 13:37 - 13:41 East Coast USA Time

  Abstract Introduction
  

  Speaker: Bruno Paiva, PhD – Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
• 13:41 - 13:59 East Coast USA Time

  (OA-30) Single-Cell Immune Landscape Associated with Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction Efficacy in Newly Diagnosed Myeloma
  

  Abstract Presenter: Ludovic Martinet, PhD (he/him/his) – Cancer research center of Toulouse, iuct-oncopole, CHU Toulouse
• 13:59 - 14:03 East Coast USA Time

  Abstract Introduction
  

  Speaker: Jill Corre, PharmD PhD (she/her/hers) – Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
• 14:03 - 14:21 East Coast USA Time

  (OA-33) High-Risk Genomic Consensus Model Validation in a Large Cohort of Newly Diagnosed Multiple Myeloma Patients Using Next Generation Sequencing
  

  Abstract Presenter: Anais Schavgoulidze, PharmD PhD (she/her/hers) – IUCT Oncopole Toulouse
• 14:21 - 14:25 East Coast USA Time

  Abstract Introduction
  

  Speaker: Richard LeBlanc, MD (he/him/his) – Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
• 14:25 - 14:43 East Coast USA Time

  (OA-68) Safety and Efficacy of Linvoseltamab (LINVO) in Patients (Pts) with High-risk Smoldering Multiple Myeloma (HR-SMM): First Results from the Phase 2 LINKER-SMM1 Trial
  

  Abstract Presenter: Paula Rodriguez-Otero, MD PhD (she/her/hers) – Clinica Universidad de Navarra
• 14:43 - 14:47 East Coast USA Time

  Abstract Introduction
  

  Speaker: Hira Mian, MD (she/her/hers) – McMaster University, Hamilton, ON, Canada
• 14:47 - 15:05 East Coast USA Time

  (OA-61) A Randomized Phase 2 Study of Daratumumab, Lenalidomide, Ixazomib, and Dexamethasone in Transplant-Ineligible/Deferred Patients with Newly Diagnosed Multiple Myeloma: Alliance Foundation Trial 41
  

  Abstract Presenter: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center